Venture Capital

The 2026 auto show reveals a market in flux. Hybrids are back, EVs adapt post-rebate, and the hunt for affordable cars intensifies. What's next?

The global asset manager appoints Kikuo Shirose to lead its Japan office, signaling a deep push into the nation's booming real assets and alternatives market.

A Boston biotech, armed with $62M and a new name, unveils a plan to build a universal model of the cell, aiming to predict and control its behavior.

Backed by Frazier Healthcare Partners, the new CareTria aims to slash patient wait times for medication with a powerful, end-to-end technology platform.

Pharma giant Lilly and AI biotech BigHat are teaming up to solve a critical flaw in AI drug discovery, aiming to unlock a new generation of therapies.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

Formerly Pure Harvest, Mixie Technologies acquires a stake in digital twin firm HoloTwin, signaling a major strategic shift into AI and platform solutions.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new partnership gives NWS forecasters unprecedented views into weather blind spots, boosting warning capabilities for 130 million Americans.

A new partnership aims to use advanced nuclear reactors to produce life-saving medical isotopes on U.S. soil, tackling a critical national vulnerability.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Retail's next frontier is here. AI agents are moving beyond chatbots to autonomously discover, select, and purchase goods on your behalf. Here's what's coming.

With a massive $200M Series C, Soley Therapeutics is using its AI cell-sensing platform to fast-track novel cancer drugs from code to clinic.

With its revolutionary Prime Editing tech showing promise, Prime Medicine faces a pivotal moment at the J.P. Morgan conference. Can it justify its new strategy?

A new Deloitte study shows EV interest stalling as affordability woes and practical concerns push buyers back to gas and hybrids, rocking brand loyalty.

Kelonia Therapeutics gets the FDA green light to expand trials for its in vivo CAR-T therapy, a single-infusion treatment that could redefine cancer care.

As its SPAC merger with Churchill Capital IX nears, PlusAI will meet investors at a key conference, showcasing its autonomous trucking tech and strategy.

A federal grant for a Quebec mine signals Canada's strategic move to build a domestic LFP battery supply chain and challenge China's market dominance.

Anterix hires a new product chief and sees its COO depart, signaling a major pivot from spectrum provider to a full-service solutions leader for utilities.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.